Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy- results of a longitudinal study.

Body mass index Head and neck cancer Intensity-modulated radiotherapy Late toxicity Long term study Lymphedema Quality of life

Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
02 Jul 2020
Historique:
received: 16 04 2020
revised: 05 06 2020
accepted: 07 06 2020
pubmed: 6 7 2020
medline: 6 7 2020
entrez: 6 7 2020
Statut: aheadofprint

Résumé

Treatment-associated lymphedema is a common side effect after multimodal therapy for locally advanced head and neck cancer (LAHNC). This study aims to evaluate potential prognostic factors for head and neck lymphedema (HNL) and its potential impact on clinical outcome. This is a prospective data registry analysis on 280 patients treated for locally advanced head and neck cancer (LAHNC). All patients received surgery and risk-adapted platinum-based adjuvant intensity modulated radio(chemo)therapy (R(C)T, IMRT). Treatment- related toxicity was prospectively registered in a data base in regular intervals (baseline 3 months after R(C)T, every 3 months for 3 years, and every 6 months thereafter) and documented according to RTOG/EORTC toxicity criteria. Predictive for any grade HNL 3 months after R(C)T were age, BMI, number of removed nodes and RT modality. Multivariable logistic regression analysis showed that in the acute toxicity phase (3 months after R(C)T) higher body mass index (BMI), extracapsular spread (ECE), linac-based IMRT, bilateral treatment to the neck (surgery and RT), and the addition of chemotherapy increase the risk for grade 2 HNL. For chronic HNL, higher BMI, linac-based IMRT and ECE were predictive for grade 2 HNL. Higher BMI is associated with better local control rates. Advanced age and ECE had a negative impact on OS. HNL is a common acute and late side effect after multimodal therapy for LAHNC. Knowing risk factors for HNL prior to therapy enables caregivers and patients to take measures prior to treatment to prevent or limit the effects of HNL.

Identifiants

pubmed: 32623355
pii: S1368-8375(20)30292-X
doi: 10.1016/j.oraloncology.2020.104856
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104856

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Silke Tribius (S)

Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address: s.tribius@asklepios.com.

Henning Pazdyka (H)

Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Pierre Tennstedt (P)

Martini Clinic, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Chia-Jung Busch (CJ)

Department of Otolaryngology and Head and Neck Surgery, Center for Clinical Neurosciences, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Henning Hanken (H)

Department of Oral & Maxillofacial Surgery, Center for Clinical Neurosciences, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Andreas Krüll (A)

Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Cordula Petersen (C)

Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Classifications MeSH